Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 21, 2026.

Oxysterol Sensing through the Receptor GPR183 Promotes the Lymphoid-Tissue-Inducing Function of Innate Lymphoid Cells and Colonic Inflammation

Johanna Emgård, Hana Kammoun, Bethania García-Cassani and 21 more

Immunity · 2018 · CC BY

doi:10.1016/j.immuni.2017.11.020

Abstract

Group 3 innate lymphoid cells (ILC3s) sense environmental signals and are critical for tissue integrity in the intestine. Yet, which signals are sensed and what receptors control ILC3 function remain poorly understood. Here, we show that ILC3s with a lymphoid-tissue-inducer (LTi) phenotype expressed G-protein-coupled receptor 183 (GPR183) and migrated to its oxysterol ligand 7α,25-hydroxycholesterol (7α,25-OHC). In mice lacking Gpr183 or 7α,25-OHC, ILC3s failed to localize to cryptopatches (CPs) and isolated lymphoid follicles (ILFs). Gpr183 deficiency in ILC3s caused a defect in CP and ILF formation in the colon, but not in the small intestine. Localized oxysterol production by fibroblastic stromal cells provided an essential signal for colonic lymphoid tissue development, and inflammation-induced increased oxysterol production caused colitis through GPR183-mediated cell recruitment. Our findings show that GPR183 promotes lymphoid organ development and indicate that oxysterol-GPR183-dependent positioning within tissues controls ILC3 activity and intestinal homeostasis.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Innate lymphoid cells (ILCs) are recently described immune cells of lymphoid origin and include cytotoxic natural killer (NK) cells and interleukin-7 receptor alpha (also known as CD127)+ subsets, which, similar to T helper (Th) lymphocytes, can be distinguished on the basis of signature transcription factors and effector cytokines: (1) ILC1s require the transcription factor T-BET and produce interferon-γ. (2) ILC2s express the transcription factor GATA3 and produce the type 2 cytokines interleukin 5 (IL-5) and IL-13. (3) ILC3s are dependent on the transcription factor RAR-related orphan receptor gamma t (RORγt) and have the ability to produce IL-17 and/or IL-22.

ILC3s are enriched in the intestine, where they maintain healthy tissue function by orchestrating lymphoid-organ development, containment of commensal bacteria, tissue repair, host defense, and regulation of adaptive immunity. ILC3s can be divided into two main populations with distinct ontogeny, transcriptional programs, and localization within the gut: (1) C-C motif chemokine receptor 6 (CCR6)− ILC3s co-expressing RORγt and T-BET are mainly found scattered throughout the lamina propria. (2) CCR6+NKp46− fetal lymphoid tissue inducer (LTi) and adult LTi-like cells expressing c-KIT (also known as CD117) seed the gut during fetal development, develop along a pathway distinct from that of other ILCs, and promote lymphoid tissue development. Accordingly, LTi cells reside in intestinal lymphoid structures, called cryptopatches (CPs) and isolated lymphoid follicles (ILFs), which are collectively referred to as solitary intestinal lymphoid tissues (SILTs). CPs are clusters of LTi-like ILC3s surrounded by dendritic cells (DCs) within a network of stromal cells, whereas ILFs additionally contain B cells. CPs and ILFs develop postnatally through the activity of adult LTi-like ILC3s that produce lymphotoxin. Whereas lymphoid organogenesis in the small intestine has been well studied, the specific factors required for SILT development in the colon, beyond lymphotoxin, are unknown.

Environmental cues, such as microbial, dietary, and neuronal signals, regulate the differentiation and function of ILC3s. However, the identities of any additional cues and the receptors that detect them remain unknown. An important class of proteins enabling cells to sense extracellular cues are G-protein-coupled receptors (GPCRs), which mediate cellular responses to diverse environmental signals. We therefore hypothesized that ILC3 function is regulated by GPCRs that recognize endogenous metabolites. In this regard, we focused on G-protein-coupled receptor 183 (GPR183, also known as EBI2), a GPCR that instructs antibody (Ab) responses in lymphoid organs through the positioning of B cells, T cells, and DCs. GPR183 is a receptor for oxysterols, hydroxylated metabolites of cholesterol, which have pleiotropic roles in lipid metabolism, immunity, and inflammation. The most potent GPR183 ligand is 7α,25-hydroxycholesterol (7α,25-OHC). Synthesizing 7α,25-OHC from cholesterol requires the enzymes cholesterol 25-hydroxylase (CH25H) and cytochrome P450, family 7, subfamily b, polypeptide 1 (CYP7B1), whereas hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 (HSD3B7) metabolizes 7α,25-OHC into bile acid precursors that lack GPR183 ligand activity. Given that GPR183 regulates immune cell migration, we reasoned that oxysterols could function as guidance cues for ILC3s.

Here, we report that ILC3s sensed oxysterols through GPR183, which was highly expressed by LTi-like ILC3s. 7α,25-OHC-synthesizing enzymes were produced by fibroblastic stromal cells found in intestinal lymphoid structures, and the GPR183 ligand 7α,25-OHC acted as a chemoattractant for ILC3s. GPR183 and 7α,25-OHC were required for ILC3 localization to lymphoid structures in the colon, and ablation of Gpr183 in ILC3s caused a defect in the formation of colonic CPs and ILFs. The same phenotype was observed in mice lacking Ch25h, demonstrating a requirement for oxysterols in lymphoid tissue organogenesis. Furthermore, 7α,25-OHC was increased by inflammatory signals, and GPR183 controlled inflammatory cell recruitment during colitis. Consequently, Gpr183-deficient mice were less susceptible to colitis in an innate model of intestinal inflammation. Our results establish a role for a lipid ligand and its cell-surface receptor in controlling ILC3 migration, lymphoid tissue development, and inflammatory responses in the intestine.

LTi-like ILC3s Highly Express GPR183 and Migrate toward 7α,25-OHC

It is unknown whether ILCs express GPR183 and whether the GPR183 ligand 7α,25-OHC regulates ILC function. To test our hypothesis that GPR183 controls ILC migration, we first determined Gpr183 expression in ILC subsets. As expected, Gpr183 mRNA was expressed in purified B cells from the spleen, but not in NK cells, whereas ILCs with an LTi phenotype (Lin−CD127+NKp46−CD4+) abundantly expressed Gpr183 (Figure 1A). To confirm these findings, we used Gpr183GFP/+ reporter mice and focused on the colon, given that it has the full spectrum of ILC subsets (Figure S1). As in the spleen, NK cells largely lacked Gpr183 mRNA, whereas other ILC types expressed Gpr183 (Figure 1B). Among all ILC subsets, CD4+ LTi-like ILC3s had the highest Gpr183 expression (Figures 1B and 1C). ILC3s from the small intestine (Figures S2A–S2C) and lymph node (Figure S2D) also expressed Gpr183. Moreover, mRNA for the GPR183 ligand-regulating enzymes CH25H, CYP7B1, and HSD3B7 was expressed in both the small intestine and colon (Figure S2E). The high Gpr183 mRNA expression in LTi-like ILC3s led us to ask whether ILC3s express functional GPR183 on the cell surface. To address this question, we performed chemotaxis assays to the known GPR183 ligand 7α,25-OHC. Splenic LTi-like ILC3s showed a typical bell-shaped chemotactic response to 7α,25-OHC (Figure 1D), demonstrating that GPR183 is functional in ILC3s. Consistent with high Gpr183 expression (Figure S2F), splenic CD4+ LTi-like ILC3s showed a greater migratory response than other cells to 7α,25-OHC (Figure 1E). Colonic ILC3s and ILC2s also migrated toward 7α,25-OHC in vitro (Figure 1F). To confirm that 7α,25-OHC drives ILC3 migration through GPR183, we examined the chemotaxis of Gpr183-deficient ILCs. For this purpose, we generated Gpr183−/− mice. LTi-like ILC3s lacking Gpr183 failed to migrate toward 7α,25-OHC (Figure 1D), indicating that ILC3 chemotaxis to oxysterol is GPR183 dependent. We concluded that high GPR183 expression enabled LTi-like ILC3s to migrate toward the chemoattractant oxysterol 7α,25-OHC.

GPR183 Expression by ILC3s Is Required for the Formation of Colonic Lymphoid Tissues

GPR183 expression in LTi-like ILC3s and B cells, which are known to localize to CPs and ILFs, suggested that GPR183+ cells were not randomly distributed in the intestine. To analyze the distribution of GPR183-expressing cells, we prepared gut tissue sections from Gpr183GFP/+ mice. We found that GPR183+ cells clustered in both CPs (mainly composed of CD90.2+ ILCs) and ILFs (also containing B220+ B cells) in the colon and small intestine (Figure 2A). The fact that ILC3s with LTi function highly expressed GPR183 led us to hypothesize that GPR183 is required for the development of intestinal lymphoid structures. To explore this hypothesis, we crossed Gpr183−/− mice with Rorc(γt)GFP transgenic mice to visualize and quantify SILTs in frozen sections. Consistent with our hypothesis, the number of CPs and ILFs was markedly lower in the colon of mice lacking Gpr183 than in co-housed Gpr183+/+ littermates (Figure 2B). Moreover, the number of colonic patches was also significantly lower in Gpr183-deficient mice (Figure 2C). In contrast, CPs and ILFs were present in the small intestine of Gpr183−/− mice (Figure 2B). GPR183 was also dispensable for the development of peripheral and mesenteric lymph nodes, as well as Peyer’s patches (Figure 2C).

To confirm that GPR183 expression in hematopoietic cells was required for CP and ILF formation, we generated bone marrow chimeras. We found that the transfer of Gpr183+/+ bone marrow into Gpr183-deficient recipients partially rescued SILT development in the colon (Figure 2D). A full rescue was not expected because LTi-like ILC3s, in contrast to B cells, are partially radioresistant, which created a mixed ILC3 compartment, consisting of donor-derived Gpr183+/+ and radioresistant Gpr183-deficient ILC3s of host origin (Figure S3). The reduction of both CPs and ILFs in Gpr183−/− mice suggested that GPR183 expression on ILC3s, rather than on B cells, was required for colonic lymphoid tissue development. To exclude a role of B-cell-expressed GPR183, we bred Gpr183−/− mice onto a Rag1-deficient background. The number of colonic CPs was significantly lower in Rag1- and Gpr183-double deficient mice than in Rag1-deficient Gpr183-sufficient mice (Figure 2E).

Our finding that ILC2s expressed Gpr183 mRNA (Figure 1B) and migrated toward 7α,25-OHC (Figure 1F) allowed us to predict that ILC2s also reside in colonic lymphoid structures. We confirmed this prediction by staining with α-GATA3 (Figure S4A) and α-KLRG1 antibodies (Abs) (Figure S4B). To determine whether ILC3-expressed GPR183 was required for CP and ILF formation, we generated Rorc-cre Gpr183flox/flox mice, where Gpr183 expression was ablated in ILC3. In these mice, T cells also lacked Gpr183, but T cells are known to be dispensable for lymphoid tissue formation in the intestine. We found that CP and ILF development in the colon, but not in the small intestine, was severely impaired in Rorc-cre Gpr183flox/flox mice, whereas Peyer’s and colonic patches were not affected (Figure 2F). Collectively, our data demonstrate that GPR183-expressing cells reside in gut lymphoid structures and that GPR183 expression by ILC3s is crucial for the formation of CPs and ILFs in the colon.

GPR183 and 7α,25-OHC Promote ILC Localization to CPs

Next, we wanted to establish how GPR183 regulates CP and ILF formation in the colon. On the basis of the fact that GPR183 controls immune cell migration, we asked whether GPR183 is required for ILC3 recruitment to CPs. To address this question, we generated mixed bone marrow chimeras by sub-lethally irradiating Rag1-deficient mice (CD45.1+) and reconstituting them with a 9:1 mixture of Gpr183+/+ or Gpr183−/− (CD45.2+) and C57BL/6 (B6) (CD45.1+) bone marrow cells (Figure S5A). This experimental setup allowed us to study Gpr183-deficient and -sufficient cells in the same environment, thereby excluding any cell-extrinsic effects on cell distribution. As expected, CPs and ILFs in mixed Gpr183+/+-B6 chimeras consisted mainly of CD45.2+ Gpr183+/+ cells (Figure 3A). In contrast, Gpr183-deficient hematopoietic cells failed to localize to CPs and ILFs in mixed Gpr183−/−-B6 chimeras, and accordingly, CPs and ILFs in these chimeras mostly contained CD45.1+ B6 cells (Figure 3A). To more specifically address whether ILC3 migration to CPs and ILFs is dependent on GPR183, we employed a similar mixed bone marrow chimera approach, by using the congenic marker CD90 (Thy1) instead of CD45 (Figure S5B), given that CD90 labels ILCs more specifically than CD45. Notably, donor-derived Gpr183−/− ILCs (CD90.2+) were largely excluded from CPs, whereas ILCs derived from Gpr183+/+ bone marrow (CD90.2+) selectively localized to CPs (Figure 3B). These observations demonstrate that GPR183 acts in a cell-autonomous manner to promote ILC localization to colonic CPs and ILFs.

To determine whether ILC positioning to CPs and ILFs is directed by 7α,25-OHC, we assessed the spatial distribution of ILC3s in mice lacking Ch25h. For this purpose, we reconstituted either Ch25h+/+ or Ch25h−/− recipients with bone marrow from Rag1-deficient Rorc(γt)GFP transgenic mice (Figure S5C). Immunofluorescence microscopy showed that donor-derived GFP+ ILC3s localized to colonic CPs in Ch25h+/+ mice, whereas donor-derived ILC3s were unable to do so in Ch25h-deficient hosts (Figure 3C). In the absence of Ch25h, donor-derived ILC3s also failed to migrate to CPs in the small intestine (Figure 3D). In contrast to in the colon, however (Figure 3C), host B cells in the small intestine formed enlarged lymphoid clusters, despite the ILC3 localization defect (Figure 3D). These findings suggest that lymphoid-tissue-inducing activity of B cells compensates for impaired ILC3 recruitment when GPR183 ligand is lacking, which subsequently allows lymphoid tissue formation in the small intestine. Combined, these data demonstrate that GPR183 and its ligand promote colonic SILT development by directing LTi-like ILC3s to sites of CP formation.

GPR183 Enhances IL-22 Production by Colonic ILC3s

Next, we asked whether altered ILC3 positioning in the absence of GPR183 causes defects in the development, homeostasis, or function of ILC3s. There was no general developmental defect, given that all ILC subsets were present in the colon of Gpr183−/− mice (Figures S6A and S6B). Furthermore, flow-cytometric analysis revealed that the number of individual ILC3 subsets was not significantly different between Gpr183+/+ mice and mice lacking Gpr183 (Figure S6C). We next investigated the expression of lymphotoxin, the key factor for lymphoid organogenesis. To exclude a lymphocyte source of lymphotoxin, we performed this analysis in Rag1-deficient Gpr183−/− mice. Lymphotoxin beta (Ltb) mRNA expression in the colon was ∼3-fold lower in Rag1−/− mice lacking Gpr183 than in Gpr183+/+ Rag1−/− mice (Figure S6D). CP and ILF formation is also dependent on aryl hydrocarbon receptor (AHR). However, the amount of Ahr mRNA in the colon was not different between Rag1-deficient Gpr183+/+ and Gpr183−/− mice (Figure S6D). In contrast to whole colon tissue, purified Gpr183-deficient ILC3s from Rag1−/− mice expressed normal amounts of Lta and Ltb mRNA (Figure S6E). The membrane-bound form of lymphotoxin (LTα1β2) is required for lymphoid tissue formation, and we therefore examined LTα1β2 surface expression by using a LTβ receptor (LTβR)-Fc fusion protein. This experiment was performed with ILCs from mesenteric lymph nodes given that we could not detect surface LTα1β2 in Gpr183+/+ ILC3s from the colon, most likely because the cell-isolation procedure led to a loss of LTα1β2 from the cell surface. Gpr183-deficient CD4+ LTi-like ILC3s had significantly lower amounts of LTα1β2 on the cell surface than their Gpr183-sufficient counterparts (Figure S6F). Together, our data suggest that Gpr183 deficiency causes impaired colonic lymphoid tissue formation mainly because of the inability of LTi-like ILC3s to migrate to CPs and ILFs rather than an intrinsic defect in lymphotoxin expression by ILC3s.

ILFs are important sites of immunoglobulin A (IgA) production, and the reduction of colonic lymphoid structures indicates that IgA production might be impaired in mice lacking Gpr183. To explore this possibility, we measured IgA in either untreated or T-cell-depleted Gpr183+/+ and Gpr183−/− mice. IgA concentrations in serum and feces were not significantly different between Gpr183-deficient and Gpr183-sufficient mice (Figure S6G), most likely as a result of compensatory IgA production by small intestinal lymphoid structures, which were not affected by Gpr183 deficiency (Figures 2B and 2C).

We next assessed whether Gpr183 deficiency alters the ability of ILCs to produce cytokines. IL-22 production by Gpr183-deficient ILC3s from the colon was significantly lower than production by their Gpr183+/+ counterparts (Figures 4A and 4B). In contrast, IL-22 production by Gpr183-deficient ILC3s from the small intestine was unaffected (Figures 4A and 4B). Most likely, impaired IL-22 production by Gpr183−/− ILC3s from the colon was secondary to the ILC3 migration defect and reduction of colonic CPs and ILFs when Gpr183 was lacking. Accordingly, 7α,25-OHC failed to directly modulate IL-22 production by ILC3s in vitro (Figure 4C). Moreover, the lack of Gpr183 had no effect on IL-5 and IL-17 production by intestinal ILC2s and ILC3s, respectively (Figure 4B). Finally, Gpr183−/− mice (on a Rag1−/− background) expressed less colony stimulating factor 2 (Csf2) mRNA in the colon than their Gpr183+/+ counterparts, whereas purified Gpr183-deficient ILC3s had slightly higher Csf2 expression than Gpr183+/+ ILC3s (Figure 4D). In summary, these data show that GPR183 is dispensable for IgA production but promotes IL-22 production by colonic ILC3s.

Fibroblastic Stromal Cells Provide a Local Source of 7α,25-OHC

GPR183 and its ligand 7α,25-OHC directed ILC3 migration to CPs and ILFs (Figure 3). This allowed us to predict that production of 7α,25-OHC should take place in CPs and ILFs and thereby attract GPR183+ cells. To test this prediction, we measured 7α,25-OHC-synthesizing enzymes in micro-dissected colonic CPs and ILFs (Figure S7A). Consistent with our hypothesis, we found that mRNA for the GPR183-ligand-synthesizing enzymes CH25H and CYP7B1 was significantly enriched in CPs and ILFs, whereas expression of the ligand-degrading enzyme HSD3B7 was not different between the lamina propria and CPs and ILFs (Figure 5A). Similar results were obtained for colonic (Figure S7B) and Peyer’s (Figure S7C) patches. These data suggest that local 7α,25-OHC production takes place in colonic lymphoid structures, and we therefore asked whether 7α,25-OHC promotes CP and ILF formation. To investigate this possibility, we used mice lacking Ch25h and therefore 7α,25-OHC. The number of colonic CPs and ILFs was significantly lower in Ch25h-deficient than in Ch25h+/+ mice (Figure 5B), demonstrating that 7α,25-OHC is essential for lymphoid organogenesis in the colon. In contrast, the formation of lymphoid structures in the small intestine and colonic patches was not affected by the absence of Ch25h (Figure 5B). Overall, colonic lymphoid tissue formation was less affected in Ch25h- than in Gpr183-deficient mice, most likely as a result of compensation by the alternative GPR183 ligand 7α,27-OHC, which is generated independently of CH25H.

Next, we asked which signals from the microenvironment regulate 7α,25-OHC production. Among environmental factors, the microbiota plays a pivotal role in intestinal homeostasis and immunity. Using germ-free mice, we found that Gpr183, Ch25h, and Cyp7b1 mRNA expression in the colon was independent of the microbiota (Figure 5C). Furthermore, Ltb mRNA expression in the colon was repressed by the microbiota, consistent with the observation that, in contrast to ILF formation in the small intestine, ILF formation in the colon is inhibited by the microbiota. Accordingly, the microbiota promoted expression of C-C motif chemokine ligand 20 (Ccl20) and C-X-C motif chemokine ligand 13 (Cxcl13) mRNA only in the small intestine, but not in the colon (Figure 5D). Together, these data suggest that microbiota-independent local generation of 7α,25-OHC is necessary for colonic CP and ILF formation.

Finally, we aimed to identify the cellular source of the GPR183 ligand 7α,25-OHC in the colon. To distinguish between hematopoietic- and non-hematopoietic-expressed CH25H, we generated bone marrow chimeras. Ch25h+/+ recipients injected with Ch25h−/− bone marrow had colonic Ch25h mRNA expression similar to that of Ch25h+/+ mice transplanted with Ch25h+/+ bone marrow (Figure 6A). However, Ch25h mRNA expression in Ch25h−/− mice was not rescued by the transfer of Ch25h+/+ bone marrow (Figure 6A). Similar results were obtained for the small intestine (Figure 6A). These findings demonstrate that hematopoietic-derived CH25H does not contribute to CH25H expression and that, instead, radio-resistant cells provide the main source of CH25H in the intestine. Fibroblastic stromal cells that are specialized in interacting with immune cells are found in lymphoid structures, and we hypothesized that radio-resistant stromal cells are a likely source of the GPR183 ligand 7α,25-OHC in CPs and ILFs. Consistent with this hypothesis, Ch25h and Cyp7b1 mRNA expression was much higher in non-hematopoietic-non-epithelial cells (CD45−Epcam−) than in LTi-like ILC3s, DCs, B cells, and epithelial cells (CD45−Epcam+) isolated from the colon (Figure 6B). Next, we measured expression of oxysterol-generating enzymes in different populations of colonic CD45− cells as previously described. These experiments revealed that CD34− podoplanin (PDPN, also known as gp38)+ stromal cells abundantly expressed the 7α,25-OHC-synthesizing enzymes CH25H and CYP7B1 (Figure 6B) and localized to ILFs (Figure 6C). In contrast, CD34+PDPN+ stromal cells, which were located outside of ILFs (Figure 6C), had higher expression of the GPR183-ligand-degrading enzyme HSD3B7 (Figure 6B). Together, these results suggest that ILF-resident CD34−PDPN+ fibroblastic stromal cells locally produce 7α,25-OHC and that neighboring CD34+PDPN+ stromal cells act as a sink for oxysterols and thereby create a 7α,25-OHC gradient between ILFs and the surrounding lamina propria. Finally, using Cxcl13-EYFP reporter mice, we found that CXCL13+PDPN+CD31− stromal cells clustered in ILFs (Figures S7D–S7F) and expressed high amounts of Ch25h and Cyp7b1 mRNA (Figure S7G). These data reinforce our concept that the GPR183 ligand 7α,25-OHC is produced by fibroblastic stromal cells that reside in CPs and ILFs. We conclude that production of 7α,25-OHC by fibroblastic stromal cells provides a critical local signal for the development of lymphoid structures in the colon.

GPR183 Expression in Innate Immune Cells Promotes Colitis

Our results so far have established a role for the oxysterol-GPR183 pathway in lymphoid tissue formation in the steady-state colon. Consequently, we asked whether this pathway has a similar function during inflammation, which causes immune cell infiltration and tissue remodeling. This seemed particularly relevant given that hyperplastic lymphoid aggregates occur in human inflammatory bowel disease (IBD), and polymorphisms in Gpr183 have been associated with IBD. We first examined whether local inflammation affects the production of GPR183 ligands in the colon. For this purpose, we used a model of innate colitis in which intestinal inflammation is induced in T- and B-cell-deficient mice by the administration of an agonistic CD40 Ab. Compared with PBS-treated Rag1−/− mice, mice treated with CD40 Ab showed rapidly increased Ch25h mRNA expression within 24 hr but repressed Hsd3b7 expression (Figure 7A). This pattern allowed us to predict that the amount of 7α,25-OHC in the colon would increase in response to CD40-Ab-induced inflammation. To test this prediction, we quantified GPR183 ligand activity in the colon by a bioassay based on the ligand-induced chemotaxis of the GPR183-transduced M12 B cell line. GPR183 ligand activity was induced by CD40 Ab treatment, given that the chemotactic response of GPR183-GFP+ M12 cells to colon homogenates rapidly increased within 24 hr after CD40 Ab injection (Figure 7B). Our results suggest that colonic inflammation activates the oxysterol-GPR183 pathway through increased production of the GPR183 ligand 7α,25-OHC. Accordingly, there was a significant correlation between CH25H and CYP7B1 expression and colonic inflammation (as measured by CXCL8 expression) in humans with ulcerative colitis (Figure 7C).

In the CD40-Ab-induced colitis model, mobilization of ILC3s from CPs into adjacent tissue and recruitment of inflammatory monocytes result in the formation of characteristic inflammatory foci. The timing of inflammation-induced production of GPR183 ligands coincided with the movement of ILC3s out of CPs and the formation of inflammatory foci. We therefore used Rag1-deficient Gpr183GFP/+ mice to examine whether GPR183+ cells localize to inflammatory infiltrates. Fluorescence microscopy of inflamed colon tissue showed that CD40-Ab-induced inflammatory foci at day 7 contained GPR183-expressing myeloid cells and ILCs (Figure 7D). These findings raise the possibility that GPR183-dependent immune cell migration promotes intestinal inflammation. To determine whether GPR183-expressing cells contribute to colitis, we treated Rag1-deficient Gpr183−/− and littermate Gpr183+/+ mice with CD40 Ab and assessed inflammation by histology on day 7. As expected, Gpr183+/+Rag1−/− mice treated with CD40 Ab showed numerous characteristic inflammatory foci in the proximal colon (Figure 7E). In contrast, Rag1−/− mice lacking Gpr183 had significantly fewer CD40-induced inflammatory infiltrates than Gpr183-sufficient controls (Figures 7E and 7F). Furthermore, CD40-treated Gpr183−/−Rag1−/− mice developed only mild colitis with an inflammation score similar to that of PBS-treated Gpr183+/+Rag1−/− mice (Figure 7F). Overall, our data demonstrate that inflammatory signals stimulate local oxysterol production and cause colitis through GPR183-dependent activation of ILC migration, myeloid cell recruitment, and tissue remodeling.

Discussion

Little is known regarding how ILCs directly sense signals from their environment and which signaling pathways enable ILCs to perform tissue remodeling. Our work demonstrates that LTi-like ILC3s were controlled by oxysterols that signal through the receptor GPR183. This instructs ILC3 positioning and lymphoid tissue formation in the colon. We propose a model where local generation of 7α,25-OHC by fibroblastic stromal cells attracts GPR183-expressing LTi-like ILC3s to sites of CP formation. This process positions LTα1β2+ ILC3s for crosstalk with LTβR+ stromal cells, which promotes the recruitment of GPR183-expressing B cells, to complete ILF formation. Moreover, our study provides information on the mechanisms that control the spatial and functional compartmentalization of ILC3s in the intestine. After homing to the intestine, ILC3s segregate into two distinct locations. Localization of NKp46+ ILC3s to the villi of the lamina propria occurs in a CXCL16-CXCR6-dependent manner, which supports epithelial defense through the production of IL-22. We have shown that GPR183 and its ligand 7α,25-OHC position LTi-like ILC3s to colonic CPs, where these cells promote lymphoid tissue formation.

Previous studies have established an essential function for GPR183 and its ligand 7α,25-OHC in lymphoid organs and humoral immunity. We have now demonstrated a role for GPR183 and oxysterols in lymphoid tissue development in the large intestine. Thus, our study has established a broader function of the oxysterol-GPR183-ligand-receptor system by linking GPR183-mediated cell positioning to tissue reorganization during steady-state homeostasis and inflammation. Whereas the signals regulating the formation of SILTs in the small intestine are well known, those in the colon have remained poorly understood. As in the small intestine, LTi-like ILC3s and LTα1β2 are required for colonic lymphoid organogenesis. However, the microbiota and receptor activator of NF-κB ligand (RANKL)-RANK, CXCL13-CXCR5, and CCL20-CCR6 are required for ILF development only in the small intestine. Accordingly, we have described a colon-specific pathway governing the postnatal development of lymphoid tissues.

One question relates to our finding that oxysterol-GPR183 signaling is critical for CP and ILF formation in the colon but dispensable in the small intestine. GPR183 and its ligand were expressed in both the small and large intestines. Moreover, 7α,25-OHC was required for ILC3 migration to CPs not only in the colon but also in the small intestine. Despite this, lymphoid tissue development in the small intestine was normal in mice lacking 7α,25-OHC. Together, our observations indicate that, as a compensatory response, B cells form lymphoid follicles when ILC3s are unable to migrate to CPs as a result of a lack of GPR183 ligand. This notion is supported by previous studies demonstrating lymphoid-tissue-inducing activity of B cells and compensatory lymphoid tissue formation when ILC3s are absent or when LTβR signaling is blocked in utero. This process must be driven by factors that operate specifically in the small intestine, because we observed compensatory B cell cluster formation only in the small intestine, but not in the colon. Such factors are the microbiota, CCL20, and CXCL13, which are all dispensable for ILC3 recruitment and CP formation but essential for B cell recruitment and ILF formation in the small intestine. In conclusion, we favor the concept that the 7α,25-OHC-GPR183 pathway is active, but not absolutely required for lymphoid tissue formation, in the small intestine because other redundant factors are sufficient in the absence of GPR183 ligand.

Recent studies support the concept that dietary metabolites, such as retinoids and AHR ligands, regulate ILC3 function. These metabolites act through intracellular nuclear receptors that function as transcription factors, thereby controlling ILC activity through the stimulation of specific transcriptional programs. We have now shown that endogenous metabolites derived from cholesterol control ILC3 function by binding to a cell-surface receptor (GPR183). Previously, it was found that 7α,27-OHC and 7β,27-OHC can act as endogenous RORγt agonists and thereby regulate Th17 differentiation. More recently, it was reported that CYP51-dependent intermediates in cholesterol biosynthesis are ligands for RORγt. Chemically distinct cholesterol metabolites can therefore be sensed intracellularly through RORγt (modulating cell differentiation) and extracellularly through GPR183 (controlling ILC3 migration).

ILC3s have been implicated in gut inflammation in various mouse models of colitis as well as in humans with IBD. Furthermore, intestinal inflammation is associated with the expansion of lymphoid structures in the gut, and hyperplastic lymphoid aggregates have been observed in human IBD. We demonstrated that GPR183 promotes lymphoid tissue formation by ILC3s not only during steady state but also during inflammation. Our findings support the notion that GPR183 stimulates pro-inflammatory ILC3 activity in the colon by triggering an inflammatory migratory response that is reminiscent of the postnatal clustering of ILC3s during the formation of CPs and ILFs. Interestingly, a Gpr183 polymorphism has been associated with IBD in humans, supporting the idea that GPR183 promotes intestinal inflammation.

In summary, our study adds to our understanding of a pathway that regulates ILC3 migration, lymphoid tissue organogenesis, and colitis. GPR183 is a GPCR, a class of molecules that are involved in many diseases while being excellent drug targets. Therefore, our findings not only elucidate a molecular mechanism underlying ILC3 function but also point toward a possible therapeutic target for the treatment of human IBD.

Contact for Reagent and Resource Sharing

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Tim Willinger (tim.willinger@ki.se).

Mice

All mice used were on the B6 genetic background. Gpr183GFP/+ mice were previously described. Gpr183−/− and Gpr183flox/flox mice were generated at Yale University as described in Generation of Gpr183-deficient Mice below. Gpr183−/− mice were bred to Rag1−/− mice to generate Gpr183−/− Rag1−/− mice and Gpr183+/+ Rag1−/− controls. Gpr183−/− mice were also bred to Rorc(γt)GFP transgenic mice, provided by Dr. Eberl (Pasteur Institute), to generate Rorc(γt)GFP Gpr183−/− and Rorc(γt)GFP Gpr183+/+ mice. Gpr183-sufficient controls for all Gpr183-deficient strains were co-housed littermates obtained from heterozygous x heterozygous breeding. Mice were generally used at 6-12 weeks of age and littermates of the same sex were as much as possible randomly assigned to experimental groups. All mice were maintained in individually ventilated cages under specific pathogen-free conditions at Yale University and Karolinska Institutet. Germ-free B6 mice were obtained from the Core Facility for Germ-Free Research at Karolinska Institutet. All mouse experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of Yale University and the Linköping Animal Experimentation Ethics Committee.

Human Inflammatory Bowel Disease (IBD)

Six ulcerative colitis patients and eight controls (patients suspected to have IBD but upon colonoscopy diagnosed as non-IBD patients) were recruited at the Astrid Lindgren Children’s Hospital, Stockholm, Sweden, after signed informed consent was obtained. All patients (two females and four males) and controls (five females and three males) were untreated and had no other inflammatory or infectious diseases. RNA extraction was performed from frozen biopsies collected upon diagnostic colonoscopy, as previously described. Briefly, total RNA was extracted and purified from snap-frozen tissue biopsies (four 50 μm sections/patient) using the RiboPure Kit (Life Technologies). RNA was converted to cDNA using the High Capacity RNA-to-cDNA Master Mix (Applied Biosystems). cDNA was stored at −20°C until CH25H, CYP7B1, HPRT, HSD3B7, and CXCL8 mRNA expression was measured with qPCR using Taqman Gene expression assays (Applied Biosystems), according to manufacturer’s protocols. The collection of patient data and colon tissue biopsies was approved by the Ethical Review Board at Karolinska Institutet (Approval 2010/32-31/4) and the investigations were conducted according to the Helsinki Declaration.

Generation of Gpr183-deficient Mice

Mouse genomic DNA of the Gpr183 gene was isolated from B6 BAC clone RP24-395L16 (Children’s Hospital Oakland Research Institute). The targeting vector was constructed by PCR cloning of three genomic fragments into pEasy-FLIRT: a 5′ homology arm (2.6 kb) into NotI-BamHI sites, a floxed region containing exon 4 (3.5 kb) into the SalI site, and a 3′ homology arm (3.4 kb) into the AscI site. The final targeting construct was verified by a restriction digest and DNA sequencing. After linearization with SfiI, the targeting vector was electroporated into JM8 ES cells (B6 origin). Correctly targeted clones were identified by PCR screening, injected into blastocysts, and implanted into foster mothers. Chimeric mice were bred to B6 mice, and the F1 generation was screened for germline transmission with primers around LoxP site (primers E2: TGAGTCGGAGGCTAGCTTGT and F1: GTGGCTTTAATGCTGTGGAA). For the generation of Gpr183−/− mice, mice with germline transmission were bred to Tetracycline (Tet)-cre transgenic mice (JAX), which results in deletion of the of LoxP-flanked Gpr183 locus and neomycin (neo) gene because of recombinase activity in the female germline. Alternatively, the neo gene was removed by breeding to flippase recombinase transgenic mice (JAX), followed by breeding to Rorc-cre transgenic mice in order to generate Rorc-cre Gpr183flox/flox mice. Genomic DNA was isolated from tail or ear biopsies. Wild-type, floxed, and deleted Gpr183 alleles were distinguished with primers E2, F1, and B’2R (CTTGTACTGGGTTCAACGCA).

Bone Marrow Chimeras

Irradiated (2x500 cGy) Gpr183+/+, Gpr183−/−, Ch25h +/+, or Ch25h −/− recipient mice received 2x106 bone marrow cells from the indicated donor mice by intravenous (i.v.) injection. To generate mixed bone marrow chimeras, bone marrow cells from Gpr183+/+ or Gpr183−/− mice were mixed at a ratio of 9:1 with B6 cells. 2x106 cell mixture was injected i.v. into irradiated Rag1−/− (1x600 cGy) or B6 (2x500 cGy) recipients. Chimeric mice were kept on prophylactic antibiotics (Sulfatrim) for 3 weeks and analyzed 8-12 weeks after reconstitution.

Immunofluorescence Microscopy

Colons (without cecum) and small intestines were fixed in 1%–4% PFA, dehydrated in a 10%→20%→30% sucrose gradient, and frozen in OCT medium. 7-8 μm sections were cut and stained with the following Abs (all from Biolegend): CD11c (N418)-APC, CD45.1 (A20)-AF488, CD45.2 (104)-AF647, CD90.1 (OX7)-AF488, CD90.2 (30-H12)-AF647, B220 (RA3-6B2)-APC. CD34 (RAM34)-eFluor660 was from eBioscience and Syrian hamster Ab to Podoplanin was a gift from A. Farr (University of Washington, Seattle). Cy3-conjugated α-Syrian hamster IgG was from Jackson Immunoresearch. GFP expression in Gpr183GFP/+ and Rorc(γt)GFP mice was visualized with AF488-conjugated α-GFP Ab (Invitrogen). Alternatively, RORγt immunofluorescence was examined with α-RORγt (AFKJS-9) Ab using a previously published protocol. Briefly, after cell permeabilization with saponin and various blocking steps, sections were stained with primary rat α-RORγt (AFKJS-9) Ab, followed by signal amplification with secondary (FITC-conjugated donkey α-rat secondary Ab), tertiary (Alexa Fluor 488-conjugated rabbit α-fluorescein Ab), and quaternary (Alexa Fluor 488-conjugated donkey α-rabbit Ab) Abs. Finally, sections were co-stained with APC-conjugated α-B220 Ab. GATA3 immunofluorescence was determined using the same protocol with rat α-GATA3 (TWAJ) Ab and rat IgG2a isotype was used as a control. KLRG1 was detected with hamster α-KLRG1 (2F1) Ab and visualized with AF647-conjugated goat α-hamster IgG (ThermoFisher). Hamster IgG2a isotype was used as a control for KLRG1 staining. Images were acquired on a Nikon A1R confocal microscope and processed with NIS-Elements Imaging software.

Quantification of Intestinal CPs and ILFs

CPs and ILFs were quantified in the following gene-deficient strains:

(With the exception of Ch25h+/+ and Ch25h−/− mice, all controls were co-housed littermates.)

Colon (without cecum) and distal small intestine of 6 cm length were fixed and sectioned. Tissue sections were stained for RORγt and B220 to visualize CPs (RORγt+B220- clusters) and ILFs (RORγt+B220+ clusters). RORγt was detected either with AF488-conjugated α-GFP Ab in Rorc(γt)GFP Gpr183+/+ and Rorc(γt)GFP Gpr183−/− mice or with α-RORγt Ab in all other strains of mice – see Immunofluorescence Microscopy above. CPs and ILFs were counted in 20 sections taken at 80 μM intervals through the whole depth of the tissue, with the exception of colonic CPs and ILFs in Rorc(γt)GFP Gpr183+/+ and Rorc(γt)GFP Gpr183−/− mice, where 30 sections were counted (Figure 2B).

Isolation of Immune Cells and Flow Cytometry

Spleens and lymph nodes were mechanically disrupted and filtered through 100 μm nylon mesh. Lamina propria lymphocytes (LPLs) were isolated from the colon (incl. cecum) and small intestine using a standard protocol. Dissected intestines were flushed with cold PBS to remove feces and mucus, opened longitudinally, and cut into ∼1cm pieces. To remove epithelial cells, intestinal pieces were incubated twice in HBSS supplemented with 5% FCS, 10mM HEPES, and 5mM EDTA for 15 minutes (min) at 37°C (shaking). After each incubation, tubes were vortexed and the supernatant, containing epithelial cells, discarded. Pieces were then washed with RPMI 1640 medium supplemented with 10% FCS, 2mM L-Glutamine, 1% penicillin-streptomycin, and 55 μM β-mercaptoethanol (R10 medium), minced with scissors, and incubated in digestion medium (HBSS containing 5% FCS, 0.2mg/ml collagenase IV, and 0.1mg/ml DNase I) for 20 min at 37°C (shaking). After vortexing, supernatants were collected, and passed sequentially through 100 μm and 70 μm cell strainers. Digestion was repeated twice and the supernatants pooled. LPLs were then isolated with a 40%/80% Percoll gradient and washed for FACS analysis. Single-cell suspensions were stained with fluorochrome-labeled Abs (see Key Resources Table) for 20-30 min on ice. After surface staining, cells were stained with fixable viability dye-eFluor 506 (eBioscience) according to the manufacturer’s instructions. Intracellular staining for RORγt (B2D)-PE-eFluor610 (eBioscience) was performed with the FoxP3 transcription factor buffer set (eBioscience). Alternatively, Rorc(γt)GFP transgenic mice were used to detect RORγt. Cells were acquired on a LSRII Fortessa flow cytometer (BD Biosciences) and analyzed with FlowJoV10 software.

LTα1β2 Cell Surface Expression

Surface LTα1β2 was detected using a LTβR-Fc chimera (R&D Systems) as described. Briefly, cells were blocked with 40 μg/ml donkey α-mouse Fab fragments (Jackson ImmunoResearch) for 20 min on ice before staining with 1 μg/ml LTβR-Fc chimera for 30 min on ice. After washing, cells were incubated for 20 min on ice with 6.5 μg/ml biotinylated donkey α-mouse IgG (Jackson ImmunoResearch). Cells were then washed, blocked with 2% mouse/rat serum, and stained with surface Ab mix including PE-conjugated streptavidin.

Intracellular Cytokine Staining

For IL-22 staining, LPLs were stimulated with 40ng/ml of recombinant IL-23 (R&D Systems) for 3 hr together with Golgi Stop (BD Biosciences). For IL-5, IL-17F and IL-17A staining, LPLs were stimulated with 100ng/ml phorbol-12-myristate 13-acetate (PMA) and 1 μg/ml Ionomycin for 3 hr in the presence of Golgi Stop at 37C, 5% CO2. Alternatively, single cell suspensions from mesenteric lymph nodes, small intestine and colon were stimulated with 20ng/ml IL-1β, 20ng/ml IL-23 and a commercially available cell stimulation cocktail (ebioscience) containing PMA, Ionomycin, Brefeldin A and Monensin in the absence (DMSO) or presence of 10nM 7α,25-OHC (Avanti Polar Lipids) for 4 hr. After stimulation, cells were first surface-stained and subsequently incubated with Fixation/Permeabilization buffer (Foxp3 Transcription Factor Staining Buffer Kit, eBioscience) at 4°C for 30 min. For intracellular transcription factor and cytokine staining after fixation, cells were incubated for 20 min at room temperature with fluorochrome-conjugated Abs (see Key Resources Table).

Cell Sorting

Cells were isolated from the colon and small intestine as previously described with modifications. Colon and small intestine sections were washed in PBS, cut into 1cm-pieces, and incubated with 20mL of HBSS containing 5% FCS, 5mM EDTA, 1mM DTT, and 15mM HEPES at 37°C for 30 min on a shaking incubator. The supernatant, i.e., the intestinal epithelial cell (IEC) fraction, was saved and the pieces were subsequently washed and incubated with 10mL of serum-free HBSS containing 0.15mg/mL Liberase TL (Roche) and 0.1mg/mL DNase I at 37°C for 45 min at 600rpm. The resulting lamina propria (LP) cell suspension was then passed through a 100 μm nylon mesh and centrifuged. For isolation of epithelial (CD45-Epcam+), CD45-Epcam-, and CD45+ cells (Figure 6B, upper panel), the IEC and LP fractions were mixed, centrifuged and stained. For isolation of ILC3s, the LP fraction was further processed for Percoll gradient separation (44%/67%, Sigma) at 600 × g for 20 min, washed and stained. In Figure 4D and Figure S6E, ILC3s were sorted from Rag1-deficient Rorc(γt)GFP Gpr183+/+ and Gpr183−/− mice and were defined as DAPI-CD45+CD11c−CD90.2+KLRG1−RORγt-GFP+ cells. In Figure 6B (middle panel), cells were sorted from B6 mice as B cells (CD45+B220+MHC class II+), LTi-like ILC3s (CD45+Lin(CD3/CD5/B220/CD11c/NK1.1) −CD127+CD90+KLRG1−CCR6+), DCs (CD45+CD11c+Class II+), and CD45−Epcam-FSChi cells. Cell populations were sorted using BD FACSAriaI (BD Biosciences).

Isolation of Stromal Cells

Colonic stromal cell subsets (Figure 6B, lower panel) were isolated by cell sorting as described. CXCL13+ stromal cells (Figures S7F and G) were isolated from Cxcl13-EYFP reporter mice as follows: Colonic tissue was harvested and incubated three times for 15 min at room temperature under constant agitation with PBS containing 5% FCS (Lonza), 5mM EDTA (Sigma), 10mM HEPES (Sigma) and 1mM DTT (PD buffer) in order to dissociate the epithelial layer. The tissue was subsequently washed with HBSS containing 10mM HEPES and digested three times for 20 min at 37°C under constant agitation with 120mg/ml collagenase P (Roche), 25mg/ml DNase I (Applichem) and 5μg/ml Dispase I (Roche) in RPMI 1640. To enrich the fraction of stromal cells, suspensions were first purified with a 30% Percoll gradient for 20 min at 1,800rpm and 4°C. Then hematopoietic cells and erythrocytes were depleted by incubating the cell suspension with MACS α-CD45 and α-Ter119 microbeads and passing through a MACS LS column (Miltenyi Biotec). Unbound single cell suspensions were used for further flow cytometric analysis with α-CD31 (390)-PerCP/Cy5.5 and α-Podoplanin (8.1.1)-PE Abs (Biolegend) and cell sorting was performed via Bio-Rad S3 cell sorter.

Chemotaxis Assays

Splenocytes or LPLs from the colon were rested in migration medium (RPMI 1640/0.5% fatty acid-free BSA (Sigma)/10mM HEPES) for 30 min at 37°C/5% CO2. Migration of 1-2x106 input cells through 5 μM Transwells (Corning) in response to the indicated concentrations of 7α,25-OHC (Avanti Polar Lipids) was assessed after 3-4 hr. Cells in the bottom chamber were stained with fluorochrome-conjugated Abs to identify LTi-like ILC3s (CD45+CD11b−CD11c−Gr-1−CD90.2+CD127+NK1.1−) by flow cytometry (Figure 1D). In Figure 1E, Rag1-deficient Rorc(γt)GFP transgenic mice were used and the following cell populations identified: NK cells (B220−CD3−CD5−CD11c−RORγt-GFP−NK1.1+); ILC2s (B220−CD3−CD5−CD11c−RORγt-GFP−NK1.1−KLRG1+); CCR6− ILC3s (B220−CD3−CD5−CD11c−RORγt-GFP+CCR6−); CD4+ LTi-like ILC3s (B220−CD3−CD5−CD11c−RORγt-GFP+CCR6+CD117+CD4+). For B cell (TCRβ−CD4−CD11b−CD11c−Ly6G−B220+) chemotaxis B6 mice were used. In Figure 1F, NK cells (B220−CD11c−CD127−NK1.1+), ILC2s (B220−CD11c−CD127+CD90.2+NK1.1−KLRG1+), and ILC3s (B220−CD11c−CD127+CD90.2+NK1.1−KLRG1−CD45mid) were identified in Rag1−/− mice. The chemotactic response was measured either as frequency of cells compared to input (Figure 1D) or as relative migration, i.e., number of cells migrated toward 7α,25-OHC compared to medium (Figures 1E and 1F). To measure GPR183 ligand activity, the chemotaxis of the M12 B cell line transduced with GPR183-GFP toward colon homogenates was examined as described.

IgA Production

Co-housed Gpr183+/+ and Gpr183−/− mice littermates were either left untreated or received a total of five intraperitoneal (i.p.) injections of 100 μg α-TCRβ (H57-597) Ab (Bio X Cell) every three days. Three days after the last injection, sera and feces were collected. IgA concentrations were determined in homogenized feces and sera by sandwich ELISA using goat α-mouse IgA alpha chain Abs (Abcam). Mouse IgA kappa (Abcam) was used as a standard.

Quantitative RT-PCR

Total RNA was extracted from colon tissue (∼1cm piece) or purified cells with either TRIzol reagent (Invitrogen) or RNeasy Micro Kit (QIAGEN) and used for cDNA synthesis with the SuperScript First-Strand Synthesis System (Invitrogen), iScript cDNA Synthesis Kit (BioRad), or High-Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems). Quantitative RT-PCR was performed on a 7500 Fast Real-Time PCR system or PCRQuant Studio 5 Real-Time PCR system (Applied Biosystems) with primer-probe sets purchased from Applied Biosystems (Ahr, Ch25h, Ccl20, Csf2, Cxcl13, Cyp7b1, Gpr183, Hsd3b7, Lta, Ltb) or Sigma (Hprt). Alternatively, quantitative PCR was performed using Light Cycler 480 SYBR Green I Master mix (Roche Diagnosis) on a LightCycler 480 II machine (Roche Diagnosis). Expression levels were measured using following primers: Ch25h Fw-GCGACGCTACAAGATCCA, Rv-CACGAACACCAGGTGCTG; Cyp7b1 Fw-TTCCTCCACTCATACACAATG, Rv-CGTGCTTTTCTTCTTACCATC; Hsd3b7 Fw-ACCATCCACAAAGTCAACG, Rv-TCTTCATTGCCCCTGTAGA; and QIAGEN Quantitect primer for Hprt (ENSMUSG00000025630).

Gene Expression in Colonic Lymphoid Structures

Intestines from human CD2GFP transgenic mice were flushed with cold PBS (GIBCO) and opened longitudinally. Mucus and epithelium were scraped mechanically using 1.5 mm coverslips (Thermo Scientific). Under a fluorescence Stereo Lumar Zeiss V12 microscope, intestines were imaged with a NeoLumar S 0.8x objective using the GFP filter. CPs, ILFs, colonic patches, and Peyer’s patches were dissected using a surgical blade (Swann-Morton). Tissues were collected in cold RPMI supplemented with 1% HEPES, sodium pyruvate, glutamine, streptomycin and penicillin and 0.1% β-mercaptoethanol (GIBCO). After tissue dissection, supplemented media was removed and tissues were snap-frozen using liquid nitrogen and dry ice for later RNA extraction.

Colon Histology Cxcl13-EYFP Reporter Mice

Colons were fixed with 4% paraformaldehyde (Merck) in PBS under agitation at 4°C. Fixed colons were further washed with PBS containing 1% Triton X-100 (Sigma) and 2% FCS (Sigma) overnight at 4°C. Samples were further processed with FIX&PERM cell fixation & permeabilization kit (Thermo Fischer) for RORγt staining. Briefly, samples were incubated with 1x fixation/permeabilization buffer overnight. After washing with permeabilization buffer, samples were stained with rat α-RORγt (AFKJS-9) Ab (eBioscience) for 2 hr at 4°C. Samples were then stained with biotin conjugated α-rat secondary Ab overnight after washing with permeabilization buffer. Finally, samples were incubated with Cy3-conjugated streptavidin (Jackson ImmunoResearch) and AF647-conjugated α-B220 (RA3-6B2) Ab (Biolegend) for 2 hr. Podoplanin was detected with 8.1.1 Ab (Biolegend). Microscopy analysis was performed using a confocal microscope (Zeiss LSM-710) and images were processed with ZEN 2010 software (Carl Zeiss) and Imaris (Bitplane).

Colitis Model

Colitis was induced by i.p. injection of 100 μg CD40 (FGK45) Ab (Bio X Cell) into mice on a Rag1-deficient background as described. At the indicated time points, proximal colons were harvested for RNA extraction, chemotaxis assay, immunofluorescence microscopy, or fixed in 3.7% formalin for histological analysis. Gut inflammation was assessed in paraffin-embedded colon sections stained with H&E. Inflammatory foci were identified as clusters of leukocytes near/at the tip of colonic folds in the proximal colon as described. They were distinguished from CPs by their distinct location because the latter are found at the base of the colonic folds near the crypts. Colitis score was calculated using a semiquantitative criterion-based method (score 0–6) as described. Colon sections were scored in a blinded manner.

Quantification and Statistical Analysis

Statistical parameters including number of biological replicates and repeat experiments, data dispersion and precision measures (mean and SEM) and p values for statistical significance (α = 0.05) are reported in Figures and Figure Legends. Student’s t test was used to determine statistical significance between two groups. For multigroup comparisons, we applied one-way ANOVA with post hoc testing using Tukey’s Multiple Comparison Test. Asterisk coding is indicated in Figure Legends as ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001. Statistical analysis was performed using GraphPad Prism 6.

References 51

  1. 1.

    Artis D., Spits H. The biology of innate lymphoid cells. Nature. 2015;517:293-301.

    Not in our library10.1038/nature14189

  2. 2.

    Bando J.K., Liang H.E., Locksley R.M. Identification and distribution of developing innate lymphoid cells in the fetal mouse intestine. Nat. Immunol. 2015;16:153-160.

    Not in our library10.1038/ni.3057

  3. 3.

    Buettner M., Lochner M. Development and Function of Secondary and Tertiary Lymphoid Organs in the Small Intestine and the Colon. Front. Immunol. 2016;7:342.

    Not in our library10.3389/fimmu.2016.00342

  4. 4.

    Buonocore S., Ahern P.P., Uhlig H.H., Ivanov I.I., Littman D.R., Maloy K.J., Powrie F. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature. 2010;464:1371-1375.

    Not in our library10.1038/nature08949

  5. 5.

    Cyster J.G., Dang E.V., Reboldi A., Yi T. 25-Hydroxycholesterols in innate and adaptive immunity. Nat. Rev. Immunol. 2014;14:731-743.

    Not in our library10.1038/nri3755

  6. 6.

    de Boer J., Williams A., Skavdis G., Harker N., Coles M., Tolaini M., Norton T., Williams K., Roderick K., Potocnik A.J., Kioussis D. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur. J. Immunol. 2003;33:314-325.

    Not in our library10.1002/immu.200310005

  7. 7.

    Diefenbach A., Colonna M., Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. Immunity. 2014;41:354-365.

    Not in our library10.1016/j.immuni.2014.09.005

  8. 8.

    Eberl G., Littman D.R. Thymic origin of intestinal alphabeta T cells revealed by fate mapping of RORgammat+ cells. Science. 2004;305:248-251.

    Not in our library10.1126/science.1096472

  9. 9.

    Eberl G., Marmon S., Sunshine M.J., Rennert P.D., Choi Y., Littman D.R. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat. Immunol. 2004;5:64-73.

    Not in our library10.1038/ni1022

  10. 10.

    Eberl G., Colonna M., Di Santo J.P., McKenzie A.N. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. Science. 2015;348:aaa6566.

    Not in our library10.1126/science.aaa6566

  11. 11.

    Gatto D., Paus D., Basten A., Mackay C.R., Brink R. Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. Immunity. 2009;31:259-269.

    Not in our library10.1016/j.immuni.2009.06.016

  12. 12.

    Gatto D., Wood K., Caminschi I., Murphy-Durland D., Schofield P., Christ D., Karupiah G., Brink R. The chemotactic receptor EBI2 regulates the homeostasis, localization and immunological function of splenic dendritic cells. Nat. Immunol. 2013;14:446-453.

    Not in our library10.1038/ni.2555

  13. 13.

    Geremia A., Arancibia-Cárcamo C.V., Fleming M.P., Rust N., Singh B., Mortensen N.J., Travis S.P., Powrie F. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 2011;208:1127-1133.

    Not in our library10.1084/jem.20101712

  14. 14.

    Hamada H., Hiroi T., Nishiyama Y., Takahashi H., Masunaga Y., Hachimura S., Kaminogawa S., Takahashi-Iwanaga H., Iwanaga T., Kiyono H. Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J. Immunol. 2002;168:57-64.

    Not in our library10.4049/jimmunol.168.1.57

  15. 15.

    Hannedouche S., Zhang J., Yi T., Shen W., Nguyen D., Pereira J.P., Guerini D., Baumgarten B.U., Roggo S., Wen B. Oxysterols direct immune cell migration via EBI2. Nature. 2011;475:524-527.

    Not in our library10.1038/nature10280

  16. 16.

    Huber S., Schramm C., Lehr H.A., Mann A., Schmitt S., Becker C., Protschka M., Galle P.R., Neurath M.F., Blessing M. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J. Immunol. 2004;173:6526-6531.

    Not in our library10.4049/jimmunol.173.11.6526

  17. 17.

    Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., Lee J.C., Schumm L.P., Sharma Y., Anderson C.A., International IBD Genetics Consortium (IIBDGC). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.

    Not in our library10.1038/nature11582

  18. 18.

    Kanamori Y., Ishimaru K., Nanno M., Maki K., Ikuta K., Nariuchi H., Ishikawa H. Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit+ IL-7R+ Thy1+ lympho-hemopoietic progenitors develop. J. Exp. Med. 1996;184:1449-1459.

    Not in our library10.1084/jem.184.4.1449

  19. 19.

    Kelly L.M., Pereira J.P., Yi T., Xu Y., Cyster J.G. EBI2 guides serial movements of activated B cells and ligand activity is detectable in lymphoid and nonlymphoid tissues. J. Immunol. 2011;187:3026-3032.

    Not in our library10.4049/jimmunol.1101262

  20. 20.

    Kiss E.A., Vonarbourg C., Kopfmann S., Hobeika E., Finke D., Esser C., Diefenbach A. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science. 2011;334:1561-1565.

    Not in our library10.1126/science.1214914

  21. 21.

    Kruglov A.A., Grivennikov S.I., Kuprash D.V., Winsauer C., Prepens S., Seleznik G.M., Eberl G., Littman D.R., Heikenwalder M., Tumanov A.V., Nedospasov S.A. Nonredundant function of soluble LTα3 produced by innate lymphoid cells in intestinal homeostasis. Science. 2013;342:1243-1246.

    Not in our library10.1126/science.1243364

  22. 22.

    Kvedaraite E., Lourda M., Ideström M., Chen P., Olsson-Åkefeldt S., Forkel M., Gavhed D., Lindforss U., Mjösberg J., Henter J.I., Svensson M. Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD. Gut. 2016;65:1632-1641.

    Not in our library10.1136/gutjnl-2014-309014

  23. 23.

    Lee J.S., Cella M., McDonald K.G., Garlanda C., Kennedy G.D., Nukaya M., Mantovani A., Kopan R., Bradfield C.A., Newberry R.D., Colonna M. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat. Immunol. 2011;13:144-151.

    Not in our library10.1038/ni.2187

  24. 24.

    Li J., Lu E., Yi T., Cyster J.G. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells. Nature. 2016;533:110-114.

    Not in our library10.1038/nature17947

  25. 25.

    Liu C., Yang X.V., Wu J., Kuei C., Mani N.S., Zhang L., Yu J., Sutton S.W., Qin N., Banie H. Oxysterols direct B-cell migration through EBI2. Nature. 2011;475:519-523.

    Not in our library10.1038/nature10226

  26. 26.

    Lochner M., Peduto L., Cherrier M., Sawa S., Langa F., Varona R., Riethmacher D., Si-Tahar M., Di Santo J.P., Eberl G. In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J. Exp. Med. 2008;205:1381-1393.

    Not in our library10.1084/jem.20080034

  27. 27.

    Lu E., Dang E.V., McDonald J.G., Cyster J.G. Distinct oxysterol requirements for positioning naïve and activated dendritic cells in the spleen. Sci. Immunol. 2017;2:eaal5237.

    Not in our library10.1126/sciimmunol.aal5237

  28. 28.

    Luci C., Reynders A., Ivanov I.I., Cognet C., Chiche L., Chasson L., Hardwigsen J., Anguiano E., Banchereau J., Chaussabel D. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat. Immunol. 2009;10:75-82.

    Not in our library10.1038/ni.1681

  29. 29.
  30. 30.

    McKenzie A.N.J., Spits H., Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity. 2014;41:366-374.

    Not in our library10.1016/j.immuni.2014.09.006

  31. 31.

    Mebius R.E., Rennert P., Weissman I.L. Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity. 1997;7:493-504.

    Not in our library10.1016/s1074-7613(00)80371-4

  32. 32.

    Onder L., Mörbe U., Pikor N., Novkovic M., Cheng H.W., Hehlgans T., Pfeffer K., Becher B., Waisman A., Rülicke T. Lymphatic Endothelial Cells Control Initiation of Lymph Node Organogenesis. Immunity. 2017;47:80-92.e4.

    Not in our library10.1016/j.immuni.2017.05.008

  33. 33.
  34. 34.

    Pereira J.P., Kelly L.M., Xu Y., Cyster J.G. EBI2 mediates B cell segregation between the outer and centre follicle. Nature. 2009;460:1122-1126.

    Not in our library10.1038/nature08226

  35. 35.
  36. 36.

    Randall T.D., Mebius R.E. The development and function of mucosal lymphoid tissues: a balancing act with micro-organisms. Mucosal Immunol. 2014;7:455-466.

    Not in our library10.1038/mi.2014.11

  37. 37.

    Sanos S.L., Bui V.L., Mortha A., Oberle K., Heners C., Johner C., Diefenbach A. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat. Immunol. 2009;10:83-91.

    Not in our library10.1038/ni.1684

  38. 38.

    Santori F.R., Huang P., van de Pavert S.A., Douglass E.F., Leaver D.J., Haubrich B.A., Keber R., Lorbek G., Konijn T., Rosales B.N. Identification of natural RORγ ligands that regulate the development of lymphoid cells. Cell Metab. 2015;21:286-297.

    Not in our library10.1016/j.cmet.2015.01.004

  39. 39.

    Satoh-Takayama N., Vosshenrich C.A., Lesjean-Pottier S., Sawa S., Lochner M., Rattis F., Mention J.J., Thiam K., Cerf-Bensussan N., Mandelboim O. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity. 2008;29:958-970.

    Not in our library10.1016/j.immuni.2008.11.001

  40. 40.

    Satoh-Takayama N., Serafini N., Verrier T., Rekiki A., Renauld J.C., Frankel G., Di Santo J.P. The chemokine receptor CXCR6 controls the functional topography of interleukin-22 producing intestinal innate lymphoid cells. Immunity. 2014;41:776-788.

    Not in our library10.1016/j.immuni.2014.10.007

All 51 references

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.